We appreciate the comments of Sherrick. We agree that medication decision making is complex and that shared decision making with patients is an essential aspect of good patient care. However, research on medical decision making suggests that the majority of physicians (65% in one study1) do not discuss medication expenses with patients. Furthermore, if financial considerations from the patient perspective alone were the primary factor determining biologic drug prescription decisions, one might expect that the proportion of patients with public insurance who received prescriptions for etanercept would be smaller than the 26% observed in our sample.
DeWitt EM, Glick HA, Albert DA, Wolfe F. Etanercept or Infliximab: The Patient's Considerations—Reply. Arch Intern Med. 2006;166(13):1418. doi:10.1001/archinte.166.13.1418-b
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: